Dermata Therapeutics, Inc. (DRMA) 10-Year Financial Performance & Capital Metrics

DRMA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutDermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.Show more

Revenue $0
EBITDA -$12M
Net Income -$12M -57.6%
EPS (Diluted) -80.32 +79.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -310.44% -146.5%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 13 (bottom 13%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM21.5%

EPS CAGR

10Y-

5Y-

3Y-

TTM79.61%

ROCE

10Y Avg-419.22%

5Y Avg-198.21%

3Y Avg-188.69%

Latest-316.15%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	1.35K	322	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-1.35K	-322	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	0.76%	1%	-	-	-
Operating Expenses+	4.47M	3.17M	7.86M	9.67M	8.04M	12.51M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	1.85M	1.56M	4.4M	4.02M	3.97M	4.31M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	2.62M	1.61M	3.46M	5.65M	4.07M	8.2M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-4.47M	-3.17M	-7.86M	-9.67M	-8.04M	-12.51M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	0.29%	-1.48%	-0.23%	0.17%	-0.56%
EBITDA+	-4.47M	-3.17M	-7.86M	-9.61M	0	-12.29M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	0.29%	-1.48%	-0.22%	1%	-
D&A (Non-Cash Add-back)	1.35K	322	0	0	8.04M	0
EBIT	-4.47M	-3.04M	-7.86M	-9.61M	-7.79M	-12.29M
Net Interest Income+	-250K	-197K	-45.57K	63.57K	247.22K	225.78K
Interest Income	0	197	46	0	247.22K	225.78K
Interest Expense	250.75K	197.27K	45.61K	-63.57K	0	0
Other Income/Expense	-250.75K	-63.68K	-45.61K	63.57K	247.22K	225.78K
Pretax Income+	-4.72M	-3.24M	-7.9M	-9.61M	-7.79M	-12.29M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-4.72M	-3.24M	-7.9M	-9.61M	-7.79M	-12.29M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	0.31%	-1.44%	-0.22%	0.19%	-0.58%
Net Income (Continuing)	-4.72M	-3.24M	-7.9M	-9.61M	-7.79M	-12.29M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-95.50	-932.64	-152.70	-139.20	-399.81	-80.32
EPS Growth %	-	-8.77%	0.84%	0.09%	-1.87%	0.8%
EPS (Basic)	-95.50	-932.64	-152.70	-139.20	-401.80	-80.32
Diluted Shares Outstanding	3.47K	3.47K	52.05K	69.07K	19.5K	153K
Basic Shares Outstanding	3.47K	3.47K	52.05K	69.07K	19.4K	153K
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.07M	605.45K	11.62M	6.94M	7.98M	3.53M
Cash & Short-Term Investments	1.99M	530.4K	10.8M	6.24M	7.44M	3.16M
Cash Only	1.99M	530.4K	10.8M	6.24M	7.44M	3.16M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	8.36K	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	55.72K	105.18K	-8.36K	12.6K
Total Non-Current Assets+	322	0	0	0	0	0
Property, Plant & Equipment	322	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0
Total Assets+	2.07M	605.45K	11.62M	6.94M	7.98M	3.53M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	-0.71%	18.2%	-0.4%	0.15%	-0.56%
Total Current Liabilities+	1.72M	3.78M	1.52M	922.63K	1.62M	1.97M
Accounts Payable	337.18K	104.28K	515.25K	496.7K	866.03K	808.01K
Days Payables Outstanding	90.83K	118.2K	-	-	-	-
Short-Term Debt	730.55K	3.55M	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	500K	0	0	0	716.49K	0
Current Ratio	1.20x	0.16x	7.66x	7.53x	4.91x	1.79x
Quick Ratio	1.20x	0.16x	7.66x	7.53x	4.91x	1.79x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	553.19K	0	0	0	0	0
Long-Term Debt	553.19K	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0
Total Liabilities	2.28M	3.78M	1.52M	922.63K	1.62M	1.97M
Total Debt+	1.28M	3.55M	0	0	0	0
Net Debt	-708.06K	3.02M	-10.8M	-6.24M	-7.44M	-3.16M
Debt / Equity	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-17.83x	-16.08x	-172.25x	-	-	-
Total Equity+	-210.16K	-3.18M	10.11M	6.02M	6.36M	1.56M
Equity Growth %	-	-14.12%	4.18%	-0.4%	0.06%	-0.75%
Book Value per Share	-60.56	-915.83	194.17	87.19	325.97	10.20
Total Shareholders' Equity	-210.16K	-3.18M	10.11M	6.02M	6.36M	1.56M
Common Stock	2.35M	2.35M	833	77	26	252
Retained Earnings	-24.84M	-28.08M	-35.98M	-45.59M	-53.39M	-65.68M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.92M	-4.03M	-5.69M	-8.83M	-6.41M	-11.16M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.03%	-0.41%	-0.55%	0.27%	-0.74%
Net Income	-4.72M	-3.24M	-7.9M	-9.61M	-7.79M	-12.29M
Depreciation & Amortization	1.35K	322	0	0	0	0
Stock-Based Compensation	0	0	1.91M	930.33K	522.08K	657.65K
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	872.72K	-36.49K	14.13K	0	0	0
Working Capital Changes	-74.99K	-755.85K	289.55K	-153.58K	863.68K	466.86K
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	122.42K	-232.91K	410.97K	-18.54K	369.33K	-108.51K
Cash from Investing+	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	4.73M	2.57M	15.96M	4.28M	7.61M	6.89M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	0	287	187	1.11K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-3.92M	-4.03M	-5.69M	-8.83M	-6.41M	-11.16M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.03%	-0.41%	-0.55%	0.27%	-0.74%
FCF per Share	-1130.34	-1160.96	-109.38	-127.91	-328.73	-72.96
FCF Conversion (FCF/Net Income)	0.83x	1.24x	0.72x	0.92x	0.82x	0.91x
Interest Paid	99.01K	56.71K	1.42K	0	0	0
Taxes Paid	1.14K	3.27K	1.4K	950	950	950

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-228.09%	-119.18%	-125.96%	-310.44%
Interest Coverage	-17.83x	-16.08x	-172.25x	-	-	-
FCF Conversion	0.83x	1.24x	0.72x	0.92x	0.82x	0.91x

Frequently Asked Questions

Growth & Financials

Dermata Therapeutics, Inc. (DRMA) grew revenue by 0.0% over the past year. Growth has been modest.

Dermata Therapeutics, Inc. (DRMA) reported a net loss of $8.8M for fiscal year 2024.

Dividend & Returns

Dermata Therapeutics, Inc. (DRMA) has a return on equity (ROE) of -310.4%. Negative ROE indicates the company is unprofitable.

Dermata Therapeutics, Inc. (DRMA) had negative free cash flow of $9.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener